From the Dow Jones newswire.
Repros Theraputics said its first study of Androxal showed the drug raised men's testosterone levels to a normal range. The study was done on men who had hypogonadism resulting in low testosterone levels. The study required 75% of the men to exhibit a 24 hour average testosterone level of 300 to 1040 ng/dl at the end of a 12 week treatment. 79% reached testosterone levels in the normal range. Repros stock jumped 70% to $15.53. The drug is still in the research stage.